NCT00436033

A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,429 (actual)
• Sponsor: Pierre Fabre Medicament · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.

Conditions

• Fibromyalgia Syndrome

Interventions

Type	Name	Description
DRUG	milnacipran
DRUG	Placebo

Timeline

• Start date: 2006-02-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2007-02-16
• Last updated: 2013-07-11

Locations

13 sites across 13 countries: Czechia, Denmark, Finland, France, Germany, Italy, Norway, Poland, Portugal, Romania, Spain, Sweden, United Kingdom